What the Research Says
Intermittent fasting encompasses several eating patterns, including alternate-day fasting (ADF), the 5:2 diet (two fast days per week), and time-restricted eating (TRE, e.g., eating within a 6-hour window). All forms produce clinically significant weight loss, typically 1–8% from baseline, with reductions in energy intake of 10–30% [4]. A 2022 review noted that these diets are safe and do not increase disordered eating behaviors [1].
A comprehensive umbrella review of 11 meta-analyses (130 randomized trials, median follow-up 3 months) found 28 statistically significant associations between IF and beneficial outcomes, including reductions in body weight, fat mass, LDL cholesterol, triglycerides, fasting glucose, and blood pressure [2]. The strongest evidence (high quality) supported modified ADF for 1–2 months, which produced moderate reductions in BMI in healthy adults and those with overweight, obesity, or nonalcoholic fatty liver disease [2].
A randomized controlled trial in 101 overweight/obese adults with prediabetes compared ADF and 16/8 TRE over 3 weeks with a 3-month follow-up. Both interventions led to significantly greater reductions in body weight, BMI, and waist circumference than the control group, with ADF showing more pronounced effects on weight and BMI (p < .001) [5]. The study also found significant reductions in blood glucose and triglycerides in both IF groups [5].
Mechanisms and Caveats
The weight loss from IF is primarily driven by reduced calorie intake, but metabolic effects also play a role. Fasting periods promote the metabolism of fatty acids to ketones, which may improve insulin sensitivity and reduce oxidative stress [3]. However, IF is associated with reduced fat-free mass, which may be a concern for some individuals [2].
Evidence for long-term outcomes is limited. Most studies have short follow-up periods (median 3 months), and only 6% of significant associations were supported by moderate-quality evidence, with the majority (72%) supported by very low-quality evidence [2]. More long-term trials are needed to assess effects on cardiovascular events and mortality [2]. Additionally, IF should be avoided in certain health conditions, such as pregnancy or eating disorders [3].
本文引用的文献
Clinical application of intermittent fasting for weight loss: progress and future directions
Intermittent fasting diets (ADF, 5:2, TRE) produce clinically significant weight loss, but only a few human studies have examined health benefits; safety and practical advice are discussed.
Intermittent Fasting and Obesity-Related Health Outcomes
An umbrella review of 130 RCTs found that modified ADF for 1–2 months is supported by high-quality evidence for moderate BMI reduction in adults with overweight/obesity; 27% of associations showed significant benefits for weight and cardiometabolic outcomes.
Intermittent Fasting and Metabolic Health
Intermittent fasting schedules (ADF, full-day fasting, TRE) induce fatty acid-to-ketone metabolism, leading to weight loss and improvements in dyslipidemia and blood pressure.
Cardiometabolic Benefits of Intermittent Fasting
All forms of IF (ADF, 5:2, TRE) produce mild to moderate weight loss (1–8% from baseline) and consistent energy intake reductions (10–30%), with benefits for blood pressure, insulin resistance, and oxidative stress.
Intermittent Fasting in Weight Loss and Cardiometabolic Risk Reduction: A Randomized Controlled Trial
In a 3-week RCT with 101 overweight/obese prediabetic adults, ADF and 16/8 TRE both reduced weight, BMI, waist circumference, blood glucose, and triglycerides; ADF was more effective for weight and BMI reduction (p < .001).